RxDoctor Payments Data

Tyler Kaplan, MD

Ophthalmology · Rochester, MNNPI 1578183976

Payments from drug & device makers

$1,001in general payments, 2019–2025

Across 10 payments — averaging $100.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$174
  • Sight Sciences, Inc.$173
  • NEW World Medical,inc.$167
  • Bausch & Lomb Americas Inc.$150
  • AbbVie$134
  • Alcon$109
  • plus $94 from 2 others

What the payments were for

  • Food & beverage$1,001100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,001 in reported general payments places this provider in the 65th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$29,631
Medicare patients
204
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate15$8,101
LumiganBimatoprost11$4,699
Prednisolone Acetate72$3,457
Brinzolamide30$3,420
Brimonidine Tartrate87$2,261
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat116$1,912
Latanoprost208$1,911
Travoprost11$1,167
Dorzolamide-TimololDorzolamide/Timolol/Pf12$1,129
Timolol Maleate53$787
MoxifloxacinMoxifloxacin Hcl23$403
Dorzolamide Hcl24$392
Ketorolac Tromethamine25$375
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim21$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$134$4,69911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →